Diabetic Retinopathy

Diabetic Retinopathy – High‑Yield Study Guide for Medical Students

Definition

Diabetic retinopathy (DR) is a chronic, progressive, microvascular complication of diabetes mellitus characterized by damage to the retinal capillaries, leading to increased vascular permeability, ischemia, neovascularization, and potentially vision loss. It is broadly classified into non‑proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), with diabetic macular edema (DME) as a vision‑threatening manifestation that can occur at any stage.

Epidemiology

Diabetic retinopathy is a leading cause of preventable blindness in working‑age adults worldwide. Its prevalence increases with duration of diabetes and poor glycemic control.

• About one‑third of people with diabetes have some form of DR; a significant subset has vision‑threatening disease (PDR and/or DME).
• Incidence and progression correlate with duration of diabetes, HbA1c level, hypertension, dyslipidemia, and nephropathy.
• Both type 1 and type 2 diabetes are affected; many type 2 patients have DR at the time of diabetes diagnosis because of long asymptomatic hyperglycemia.
• Poor access to screening and ophthalmic care significantly increases risk of late presentation and irreversible vision loss.

Pathophysiology

The pathogenesis of diabetic retinopathy is driven by chronic hyperglycemia, which induces structural and functional changes in the retinal microvasculature and neuroretina.

• Hyperglycemia‑induced biochemical pathways
  • Formation of advanced glycation end products (AGEs) leading to basement membrane thickening and endothelial dysfunction.
  • Activation of the polyol pathway with sorbitol accumulation in pericytes, contributing to cell damage.
  • Oxidative stress and activation of protein kinase C (PKC), promoting vascular permeability and inflammation.
• Microvascular changes
  • Loss of pericytes (contractile support cells) weakens capillary walls and predisposes to microaneurysm formation.
  • Capillary basement membrane thickening and endothelial cell damage impair autoregulation and perfusion.
  • Capillary occlusion and non‑perfusion create areas of retinal ischemia.
• Breakdown of the blood–retinal barrier
  • Increased vascular permeability leads to retinal edema and hard exudate deposition, particularly in the macula (DME).
• Ischemia and neovascularization
  • Retinal ischemia upregulates vascular endothelial growth factor (VEGF) and other proangiogenic factors.
  • VEGF drives formation of fragile new vessels on the disc or elsewhere (PDR), which are prone to hemorrhage.
  • Fibrovascular proliferation can cause tractional retinal detachment and severe, often irreversible, vision loss.
• Neurodegeneration
  • Retinal neuronal cell loss, gliosis, and dysfunction occur early, often before visible microvascular lesions, contributing to visual dysfunction.

Classification and Staging

Clinically, diabetic retinopathy is staged based on ophthalmoscopic findings.

• No apparent retinopathy
  • Normal fundus; no specific DR lesions.
• Non‑proliferative diabetic retinopathy (NPDR)
  • Mild NPDR
    • At least one microaneurysm; few dot‑blot hemorrhages.
  • Moderate NPDR
    • More numerous microaneurysms and hemorrhages
    • Hard exudates, cotton‑wool spots, and mild intraretinal microvascular abnormalities (IRMA) may be present.
  • Severe NPDR (often summarized by the 4:2:1 rule)
    • Extensive intraretinal hemorrhages/microaneurysms in all four quadrants, or
    • Venous beading in two or more quadrants, or
    • Prominent IRMA in at least one quadrant.
    • No neovascularization yet.
• Proliferative diabetic retinopathy (PDR)
  • Presence of neovascularization on the disc (NVD) or elsewhere (NVE).
  • High‑risk PDR typically includes NVD > 1/4–1/3 disc area, or any NVD with vitreous/pre‑retinal hemorrhage, or extensive NVE with hemorrhage.
  • Associated complications: vitreous hemorrhage, tractional retinal detachment.
• Diabetic macular edema (DME)
  • Thickening of the retina and/or hard exudates in the macula region, with or without central involvement.
  • Can be present at any stage of NPDR or PDR.

Clinical Presentation

Diabetic retinopathy is often asymptomatic in early stages, which underscores the importance of screening.

• Early NPDR
  • Typically asymptomatic.
  • Patients may have normal visual acuity.
• Progressive NPDR and DME
  • Gradual, painless blurred vision, often due to DME.
  • Difficulty with reading, recognizing faces, or fine visual tasks.
  • Metamorphopsia (distortion) if fovea is involved.
• PDR
  • Sudden painless visual loss due to vitreous hemorrhage.
  • Floaters, dark spots, or cobweb‑like shadows.
  • Progressive visual field defects from tractional retinal detachment.
• Associated findings and symptoms
  • Often coexistence with other diabetic complications: neuropathy, nephropathy, cardiovascular disease.
  • Symptoms of poor metabolic control (polyuria, polydipsia) if systemic disease is not well managed.

Diagnosis

The diagnosis of diabetic retinopathy is clinical, made by retinal examination. Early identification is critical for preventing vision loss.

Screening Recommendations (high‑yield)

• Type 1 diabetes: First dilated eye exam 5 years after diagnosis, then at least annually (earlier if poor control or puberty).
• Type 2 diabetes: Dilated eye exam at diagnosis, then at least annually.
• Pregnancy in diabetics: Eye exam prior to conception or early in first trimester, with close follow‑up throughout pregnancy and postpartum, because retinopathy can progress rapidly.
• Follow‑up intervals may be shortened (e.g., 3–6 months) for moderate/severe NPDR, DME, or PDR.

Clinical Examination

• Visual acuity testing
  • Assesses functional impact and helps monitor response to treatment.
• Fundus examination
  • Dilated ophthalmoscopy using slit‑lamp biomicroscopy with a fundus lens (gold standard in clinical practice).
  • Alternatively, fundus photography (mydriatic or non‑mydriatic) is commonly used for screening programs.
  • Key lesions: microaneurysms, dot‑blot hemorrhages, flame hemorrhages, hard exudates, cotton‑wool spots, venous beading, IRMA, neovascularization, pre‑retinal/vitreous hemorrhage, fibrous proliferation.

Ancillary Investigations

• Optical coherence tomography (OCT)
  • High‑resolution cross‑sectional imaging of the retina.
  • Essential for detection and quantification of diabetic macular edema and monitoring treatment response.
• Fluorescein angiography (FA)
  • Intravenous fluorescein dye with serial fundus imaging.
  • Demonstrates microaneurysms, areas of non‑perfusion, leakage from neovascularization or macular capillaries.
  • Useful in planning laser therapy and assessing macular ischemia.
• Optical coherence tomography angiography (OCTA)
  • Non‑dye imaging of retinal and choroidal vasculature.
  • Helpful for evaluating capillary dropout and early neovascularization.

Management Overview

Management of diabetic retinopathy has two interconnected pillars:

• Systemic risk factor control: Diabetes, blood pressure, lipids, renal disease, and lifestyle.
• Ophthalmic interventions: Pharmacologic intravitreal therapies, laser photocoagulation, and vitreoretinal surgery.

Systemic Risk Factor Control

• Glycemic control
  • Tight glucose control (e.g., HbA1c ~7% individualized) reduces incidence and progression of DR, especially in type 1 diabetes.
  • Avoid rapid, extreme reductions in longstanding poor control in advanced DR, as this can transiently worsen retinopathy.
• Blood pressure control
  • ACE inhibitors or ARBs are often preferred in presence of nephropathy; BP control slows DR progression.
• Lipid management
  • Statins for cardiovascular risk reduction.
  • Fibrates (e.g., fenofibrate) have shown benefit in slowing DR progression in some studies, particularly in patients with dyslipidemia.
• Renal function optimization
  • Nephropathy and DR share similar microvascular pathology; managing CKD, albuminuria, and blood pressure is key.
• Lifestyle
  • Smoking cessation, healthy diet, regular exercise, and adherence to diabetes care plan.

Ophthalmic Management by Stage

No DR or Mild NPDR

• Observation and risk factor optimization
  • No ocular intervention required if no DME or threatening lesions.
  • Annual or individualized follow‑up with dilated exams.

Moderate to Severe NPDR

• Closer monitoring
  • Follow‑up every 3–6 months depending on severity and presence of DME.
• Treatment of DME if present (see DME section below).
• Consideration of panretinal photocoagulation (PRP) in very severe NPDR or those at high risk of progression to PDR, based on ophthalmologist assessment.

Proliferative Diabetic Retinopathy (PDR)

• Panretinal photocoagulation (PRP)
  • Laser burns applied to the peripheral retina to reduce ischemic drive and VEGF production.
  • Primary therapy for PDR; reduces risk of severe vision loss.
  • Side effects: peripheral field constriction, decreased night vision, possible macular edema.
• Intravitreal anti‑VEGF therapy
  • Agents such as bevacizumab, ranibizumab, aflibercept.
  • Can promote regression of neovascularization and are sometimes used alone or adjunctively with PRP.
  • Particularly useful in patients with coexistent DME.
• Vitreoretinal surgery
  • Pars plana vitrectomy indicated for non‑clearing vitreous hemorrhage, tractional retinal detachment involving or threatening the macula, and combined tractional/rhegmatogenous detachments.

Diabetic Macular Edema (DME)

DME is a major cause of vision loss in diabetes and requires active ophthalmic treatment once center‑involving or vision‑threatening.

• Intravitreal anti‑VEGF injections (first‑line for center‑involving DME)
  • Agents: bevacizumab, ranibizumab, aflibercept.
  • Administered monthly initially, then individualized based on response (treat‑and‑extend or PRN protocols).
  • Improve visual acuity and reduce central retinal thickness in many patients.
• Intravitreal corticosteroids
  • Triamcinolone acetonide injections or steroid implants (e.g., dexamethasone implant, fluocinolone implant).
  • Indicated in pseudophakic patients, those with suboptimal response to anti‑VEGF, or where injection burden is an issue.
  • Side effects: cataract progression, increased intraocular pressure, risk of glaucoma.
• Focal/grid laser photocoagulation
  • Historically standard of care; now often used in selected cases or as adjunct to pharmacologic therapy.
  • Targets leaking microaneurysms and diffuse leakage areas.

Monitoring and Follow‑Up

• Frequency of eye exams depends on stage of DR, presence of DME, and ongoing treatment.
• Patients undergoing anti‑VEGF or steroid therapy require frequent (often monthly initially) visits with OCT monitoring.
• Post‑PRP, follow for regression of neovascularization, development or worsening of DME, and new vitreous hemorrhage.

Key Clinical Pearls (High‑Yield for Exams)

• Duration of diabetes is the most important risk factor for DR; virtually all patients with type 1 diabetes and the majority with type 2 develop some degree of DR after decades of disease.
• Diabetic retinopathy is often asymptomatic until advanced; regular screening is essential even with normal vision.
• Non‑proliferative vs proliferative: NPDR has microaneurysms, hemorrhages, exudates, cotton‑wool spots, and IRMA; PDR is defined by neovascularization.
• Diabetic macular edema can occur at any stage and is the most common cause of vision loss in DR.
• Blood–retinal barrier breakdown underlies DME; ischemia‑driven VEGF overexpression drives neovascularization in PDR.
• Tight glycemic and blood pressure control significantly reduce incidence and progression of DR but must be balanced against hypoglycemia risk.
• Panretinal photocoagulation is the mainstay for PDR and reduces risk of severe visual loss by ablating ischemic retina and lowering VEGF production.
• Anti‑VEGF agents are first‑line for center‑involving DME and are increasingly used in PDR management.
• Pregnancy can accelerate DR progression; preconception counseling and close ophthalmic follow‑up are crucial in diabetic patients.
• Always consider the systemic context: presence of DR is a marker of generalized microvascular damage and increased cardiovascular risk.

Exam‑Oriented Quick Review

• Earliest clinical sign: Microaneurysms.
• Most common cause of visual loss: Diabetic macular edema.
• Defining feature of PDR: Neovascularization (NVD/NVE).
• Treatment of PDR: Panretinal photocoagulation ± anti‑VEGF; vitrectomy if non‑clearing vitreous hemorrhage or tractional RD.
• Treatment of center‑involving DME: Intravitreal anti‑VEGF as first‑line.
• Best prevention strategy: Systemic control of glucose, BP, and lipids + regular dilated eye exams.